

Khaleel K. Ashraf
MD, MBBS, DMRD, FACP

khaleelashraf@gmail.com kashraf@hoaallc.com [1-205-821-2467](tel:1-205-821-2467)

PROFESSIONAL ADDRESSES:

CURRENT POSITION

Hematology & Oncology Associates of Alabama, LLC
513 Brookwood Blvd, Suite 275
Birmingham, AL 35209

Consultant Hematologist/Oncologist
August 2008 - Current

Central Alabama Research
10 Old Montgomery Highway, Suite 100
Birmingham, AL 35209

Principal Investigator
April 2019 - Current

Hospice Service of Alabama
1000 Southlake Park, Suite 100
Birmingham, AL 35244

Medical Director
07/2009 - Current

UNDERGRADUATE EDUCATION:

Institution

Majors

Dates

Farook College/University of Calicut

Physics, Chemistry & Biology

08/1984 to 07/1986

MEDICAL EDUCATION:

Institution

Degree

Dates

Kozhikode Medical College/University of Calicut
Grant Medical College/University of Mumbai, India
College of Physicians & Surgeons, Mumbai, India

M.B., B.S.
M.D. (Radiology)
D.M.R.D.

09/1986 to 03/1993
08/1993 to 07/1996
08/1993 to 07/1996

RESIDENCY AND FELLOWSHIP TRAINING:

Institution

Type of Training (Specialty)

Dates

Metropolitan Hospital
New York Medical College,
New York, NY

Resident (Internal Medicine)

07/1999 to 06/2002

University of Tennessee
Memphis, TN

Fellow (Hematology/Oncology)

07/2002 to 05/2003

University of Alabama
Birmingham, AL

Fellow (Hematology/Oncology)

07/2003 to 06/2004

University of Alabama
Birmingham, AL

Fellow (Bone Marrow Transplant)

07/2004 to 07/2005

MEDICAL LICENSURE, DEA AND NPI

Alabama State License Number **25237**
Alabama State Controlled Substance Certificate
DEA Registration Number: **FA 0932372**
DEA Registration Number: **FA 0941232**
NPI Number: **1760437925**

Khaleel K. Ashraf
MD, MBBS, DMRD, FACP
khaleelashraf@gmail.com kashraf@hoaallc.com [1-205-821-2467](tel:1-205-821-2467)

BOARD AND POST GRADUATE CERTIFICATIONS:

Specialty	Issue Date	Expiration
Doctor of Medicine (Radiology) University of Mumbai	07/1996	
Board Certified in Internal Medicine (210784)	2002, 2014	2024
Board Certified in Hematology (210784)	2005, 2016	2026
Board Certified in Medical Oncology (210784)	2005, 2016	2026
FAHCT Certification in Bone Marrow Transplantation (FAHCT: The Foundation for the Accreditation of Hematopoietic Cell Therapy)	2005	
National Board of Physicians and Surgeons (Internal Medicine, Oncology and Hematology)	2015, 2019	2021

OTHER CERTIFICATIONS:

INITIAL ISSUE DATE

ECFMG Certified: 0-535-064-0	1999
American Heart Association BCLS	1999
American Heart Association ACLS	1999
Certificate of Training, UAB IRB	2003
Clinical Research Training Program (CRTP)	2005
FAHCT Inspector Course	2007

PROFESSION AND SOCIETY MEMBERSHIPS:

1993-present	Indian Medical Association (IMA)
1999-present	Member, American College of Physicians (ACP)
2000-present	American Medical Association (AMA)
2002-present	American Society of Hematology (ASH)
2002-present	American Society of Clinical Oncology (ASCO)
2004-present	American Society of Bone Marrow Transplantation (ASBMT)
2008-present	Fellow, American College of Physicians (ACP)
2017-present	Member, American Association for the Advancement of Science (AAAS)

PRIOR PROFESSIONAL POSITIONS AND APPOINTMENTS SINCE MEDICAL SCHOOL GRADUATION (In Reverse Chronological Order):

08//2005-07/2008	Assistant Professor of Medicine & Associate Scientist, Division of Hematology, Oncology and Bone Marrow Transplantation, University of Alabama at Birmingham
07/2004-07/2005	Fellow, Hematology & Oncology, Bone Marrow Transplant, UAB, THT 513K, 1530 3 rd Ave. S, Birmingham, AL 35294-3300, Ph: 205-934-2721.
07/2003-06/2004	Fellow, Hematology & Oncology, UAB WTI 226-D, 1530 3 rd Ave. S, Birmingham, AL 35294-3300. Ph. 205-934-2721
07/2002-05/2003	Fellow, Hematology & Oncology, University of Tennessee, 1331 Union Avenue, Suite 800, Memphis TN 38104. Ph: 901-722-0558
07/2000-06/2002	Resident in Internal Medicine, Metropolitan Hospital, New York Medical College, 1901 First Avenue, New York, NY 10029 Ph: 212-423-6771
07/1999-06/2000	Intern in Internal Medicine, Metropolitan Hospital, New York Medical College, 1901 First Avenue, New York, NY 10029 Ph: 212-423-6771
12/1996-06/1999	Attending Radiologist, Hala Hail Medical Clinic, P.O. Bo 1558, Hail, Saudi Arabia Ph: 966-5516-2806
09/1993-09/1996	Residency in Radiology, Grant medical College, Mumbai, India 400008. Ph: 91-22-2728482

Khaleel K. Ashraf
MD, MBBS, DMRD, FACP

khaleelashraf@gmail.com kashraf@hoaallc.com [1-205-821-2467](tel:1-205-821-2467)

04/1993-09/1993
03/1992-03/1993

MD (Dermatology) Trainee, JIPMER, Puducherry, Tamil Nadu, India
Rotating internship, Calicut Medical College, Kozhikode, Kerala, India 673008. Ph: 91-495-235-65317

TEACHING ACTIVITIES:

- Local Moderator, ACESS Physician Network (Multiple meetings, Birmingham, AL 2018, 2019)
- Attending physician at the weekly Monday morning case conference of the Hematology-Oncology fellows (08/01/2005-07/31/2008).
- Attending physician at the Tuesday board review courses for Hematology-Oncology fellows (08/01/2005-07/31/2008).
- Attending physician at the Thursday journal club for Hematology-Oncology fellows (08/01/2005-07/31/2008).
- Attending physician at the Wednesday Heme-Path meeting for Hematology-Oncology fellows, Heme Path fellows and Pathology residents (08/01/2005-07/31/2008).
- Case presentations, reviews and journal clubs as Hematology-Oncology fellow (2002-2005).
- Medical student and resident education (1999-2008).
- Involvement in the conduct of morning rounds as Assistant Chief Medical Resident during third year Internal Medicine residency (2002)

HOSPITAL/UNIVERSITY AND NATIONAL COMMITTEE APPOINTMENTS:

1. Honorary Faculty, Health City University, Saint Lucia (3/2019 – To date)
2. Brookwood Hospital Credentials Committee (01/2013 – To date)
3. Brookwood Hospital Transfusion Committee (01/2009 – To date)
4. Institutional Review Board, Brookwood Hospital (01/2009 – To date)
5. Oncology Performance Improvement Committee (01/2009 – To date)
6. Team leader, Department of Medicine Junior Faculty and Fellows Advisory Focus Group for the implementation of IMPACT, the new hospital wide EMR system 2007-08.
7. Divisional representative from Hematology-Oncology in the Department of Medicine Junior Faculty Advisory Committee, 2007 – 08
8. American Board of Internal Medicine – relevance reviewer, Medical Oncology (2006, 2007, 2008)
9. American Board of Internal Medicine – relevance reviewer, Hematology (2006, 2007, 2008)
10. CIBMTR Chronic Leukemia Working Committee (2007, 2008)
11. CIBMTR Graft Sources and Manipulation Working Committee (2007, 2008)
12. CIBMTR Non-Malignant Marrow Disorders Working Committee (2005, 2007, 2008)
13. UAB Heme Malignancy Working Group (2005 -2007, 2008)
14. UAB Graduate Faculty member on MS dissertation titled "*Comparison of Telomeric Repeat Amplification Protocol (TRAP) Assay to cytology as a screening method for Bladder Cancer*"
15. Judging committee, UAB Department of Medicine 23rd Annual Trainee research symposium (2007, 2008)
16. Fellowship Advisory Committee, UAB Division of Hematology-Oncology, 2007, 2008
17. Grant reviewer for Children's Center for Research innovation (CCRI), 2007
18. Editorial review, Clinical care options, 2006

HONORS AND AWARDS:

- Award for Honor for Excellence, National Institute of Medicine 2013, 2014
- Appointment as Consultant in Oncology, National Institute of Medicine 2013, 2014
- Appointment as Scientific Advisor, National Institute of Medicine, 2013, 2014
- Selected as Fellow, American College of Physicians, April 2008
- Selected among the "America's Top Oncologists" by the Consumer Research Council of America, 2007, 2008, 2013.
- Outstanding research fellow award, Division of Hematology-Oncology, UAB, 2005.
- Selected into UAB Clinical Research Training Program (CRTP), Class of 2005.

Khaleel K. Ashraf
MD, MBBS, DMRD, FACP

khaleelashraf@gmail.com kashraf@hoaallc.com [1-205-821-2467](tel:1-205-821-2467)

- Selected as the bone marrow transplant fellow, University of Alabama at Birmingham BMT Program for the period 07/2004-07/2005.
- Top percentile (10/10) ABIM examinations, 2002, 2014.
- Asst. Chief Medical Resident, Dept. of Medicine, Metropolitan Hospital, 2001-2002.
- Best PGY3 Resident, Dept of Medicine, Metropolitan Hospital 2001-2002.
- Best PGY2 Resident, Dept. of Medicine, Metropolitan Hospital 2001-2002.
- Finalist in the 1999 Downstate Associates Poster Competition New York Chapter of the American College of Physicians 1999.
- Top percentile, National in training examinations, Internal Medicine, 1999, 2000 & 2001.
- First rank University of Mumbai in **Radiology board** (M.D) examinations, 1996.
- First rank in Calicut Medical College and 50th in India, National Postgraduate entrance examination 1993 (top 0.1% in India).
- National merit scholarship 1984.
- School leader 1984.

PROFESSIONAL AND SOCIETY MEMBERSHIPS:

1993-present	Indian Medical Association (IMA)
1999-present	American College of Physicians (ACP)
2000-present	American Medical Association (AMA)
2002-present	American Society of Hematology (ASH)
2002-present	American Society of Clinical Oncology (ASCO)
2004-present	American Society of Bone Marrow Transplantation (ASBMT)
2008-present	Fellow of American College of Physicians

COMPLETED RESEARCH ACTIVITIES, CLINICAL TRIALS AND PUBLISHED ABSTRACTS / ARTICLES:

1. Evaluation of spinal tuberculosis using Gadolinium enhanced MRI, 1994-1996 (Post Graduate Dissertation, accepted by the University of Mumbai, 1996)
2. Phase 2 Randomized open label study of Letrozole in combination with two dose levels and schedules of Oral 779 or Letrozole alone in post-menopausal women with locally advanced or metastatic breast cancer (Sub Investigator, UT Cancer Institute, 2002-2003).
3. Randomized open-label study to assess time to Hemoglobin response of a front load dosing regimen for darbopoetin alfa compared to a weekly dose regimen of rH Erythropoietin in patients with non-myeloid malignancies receiving chemotherapy (Sub Investigator, UT Cancer Institute, 2002-2003).
4. A phase 3 randomized double-blind multi-center study of efficacy of Taxotere in combination with Aptosyn versus Taxotere and placebo in Non-Small Cell Lung Cancer after failure of prior platinum-based chemotherapy (Sub Investigator, UT Cancer Institute, 2003-2004).
5. Deep Venous Thrombosis in Patients with Lung Cancer: Patterns and Predictors of Thrombosis and Prognostic Implications: A study of 276 patients with lung cancer. Findings presented at American Society of Hematology Annual Meeting at San Diego, December 2004 (Primary author).
6. Sequential Topoisomerase Inhibition in Small Cell Lung Cancer/A Phase 1-2 clinical trial in chemotherapy naïve, refractory and relapsed disease. (2003-2005, Mentor: Dr. Francisco Robert, MD, FACP, Professor of Medicine and Director of Hematology/Oncology program at the VA Hospital, Birmingham)
7. Descriptive Analysis of Changing Toxicity Profiles for 30- and 100-Day Mortality After Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation: (HSCT) Using PO vs. IV Busulfan Based Conditioning

Khaleel K. Ashraf
MD, MBBS, DMRD, FACP

khaleelashraf@gmail.com kashraf@hoaallc.com [1-205-821-2467](tel:1-205-821-2467)

Regimens (Co Author; Abstract presented at the American Society of Bone Marrow Transplant Annual Meeting, February 2005, Keystone, CO. Manuscript in progress).

8. Impact of gCSF plus Dexamethasone mobilization and T cell dose on outcomes in Matched Related Donor PBSC transplants (Co Author; Abstract presented at the European Bone Marrow Transplant Annual Meeting, March 2005, Prague, Czech Republic. Manuscript in progress).
9. Use of Dexamethasone given to sibling donors as a way of *in vivo* purging of allo reactive donor T cells in rhg-CSF mobilized Peripheral Blood Stem Cell Transplantations resulted in significant decrease in CD3+ cells and increased CD34+ yield. (Primary author, American Society of Hematology meeting, 2007, accepted for poster presentation)
10. ASBMT risk group and CD 34+ dose predicted for the development of aGVHD in allogeneic MRD transplants when the donors who received a combined mobilization and *in vivo* TCD regimen using rhg-CFS and dexamethasone. (Primary author, American Society of Clinical Oncology meeting 2008 – abstract submitted)
11. Successful pregnancy in patient who had stem cell transplantation for aplastic anemia while undergoing active treatment for chronic GVHD – a case report. (Coauthor, American Society of Hematology meeting, 2007)
12. “Successful Treatment of T-cell Prolymphocytic Leukemia with Full-intensity Conditioning Followed by Matched Unrelated Donor Allogeneic Stem Cell Transplantation” Accepted for publication in *Clinical Advances in Hematology & Oncology*, Volume 5, Issue 11 November 2007

MANUSCRIPTS IN PREPARATION:

1. Retrospective review of patients with lung cancer and deep venous thrombosis - predictors for thrombosis and prognostic implications.
2. Mycobacterium lentiflavum infection in a patient undergoing photopheresis for chronic graft versus host disease – case report with literature review.
3. Comparison of g-CSF based stem mobilization to Cytoxan + g-CSF based mobilization in Multiple myeloma.
4. Incidence and clinical relevance of vitamin D deficiency among multiple myeloma patients referred for autologous stem cell transplantation in tertiary referral center – retrospective analysis and review of literature.

SELECTED LECTURES/PRESENTATION/MEETINGS:

- “Problem based Learning in Multiple Myeloma” Chicago, IL 11/16/2019
- “Relapsed, refractory Multiple Myeloma” Panama City, FL, 10/2/2019
- “Relapsed, refractory Multiple Myeloma” Chicago, IL, 8/21/2019
- “Karyopharm speaker training meeting” Philadelphia, PA 7/26/2019-7/27/2019
- “2019 Takeda Oncology MD Speaker Training Program” New York, NY 5/4/2019 New York, NY
- “Atypical HUS/PNH Faculty Development Meeting” Dallas, TX 3/8/2019-3/9/2019
- “Multiple Myeloma – Patient Education” Greenville, SC 3/7/2019; Fort Myers, FL 3/26/2019
- “Spleen Tyrosine Kinase Inhibition in ITP” Speaker Education, Miami 1/25/2019
- “Breast Cancer Advisory Board” 11/28/2018
- “Venous Thromboembolism in Cancer” Philadelphia, PA 10/27/2018
- “Panel discussion on Small Cell Lung Cancer” MVR CANCON 2018 Calicut, India 9/28/2018
- “Immunotherapy for Lung Cancer” MVR CANCON 2018 Calicut, India 9/28/2018
- “Ixazomib: An Oral Treatment Option for Multiple Myeloma” Athens, GA 9/20/2018
- “Rare Hematological Diseases” American Association of Physicians of Indian Origin Meeting, Birmingham, AL 9/14/2018
- “Chemotherapy Induced Nausea – Treatment Options” Indianapolis, IN, 8/24/2018
- “Treatment of DVT and PTE” Daytona Beach, FL 3/19/2018
- “Understanding Residual Disease and Immune Dysfunction in Multiple Myeloma” Webinar, 3/12/2018

Khaleel K. Ashraf
MD, MBBS, DMRD, FACP

khaleelashraf@gmail.com kashraf@hoaallc.com [1-205-821-2467](tel:1-205-821-2467)

- “Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Reduction in The Risk of Recurrent DVT and PE Following Initial Therapy” Birmingham, AL 1/31/2018
- Therapy
- “GBM Therapy Updates” Web based Training, 1/18/2018
- “Ixazomib: An Oral Treatment Option for Multiple Myeloma” West Columbia, SC 9/8/2017
- “Understanding Breakthrough Cancer Pain” Danville, VA 8/2/2017
- “Understanding Breakthrough Cancer Pain” Atlanta, GA 7/20/2017
- “Treatment of DVT and PTE” Community Hospital, Tallassee, AL 6/13/2017
- “Understanding Breakthrough Cancer Pain” Jacksonville, NC 2/20/2017
- “Understanding Breakthrough Cancer Pain” Jacksonville, NC 9/13/2016
- “Understanding Residual Disease and Immune Dysfunction in Multiple Myeloma” Johnson City, TN 9/14/2016
- “Pomalyst: A Clinical Overview”, Jackson, TN 8/30/2016
- “Understanding Residual Disease and Immune Dysfunction in Multiple Myeloma” Franklin, TN 5/15/2016
- “A Treatment option for newly diagnosed Multiple Myeloma” Tuscaloosa, AL 4/26/2016
- “Treatment of del (5q-) Myelodysplastic Syndrome” Pensacola, FL 4/21/2016
- “Low Risk MDS” Emerald Coast Hematology, Fort Walton, FL 3/16/2016
- “Understanding Residual Disease and Immune Dysfunction in Multiple Myeloma” Huntsville, AL 2/9/2016
- “Treatment of DVT and PTE”: John B Amos Cancer Center, Columbus, GA 7/14/2015
- “Treatment of Multiple Myeloma” University of MS Cancer Center, Jackson, MS 5/5/2015
- “Personalized Medicine in Oncology” – 11/2014, Brookwood Touch Patient Education
- “Future of Medicine” – 2012 Annual Alumni Lecture at Calicut Medical College, India
- “Dacogen in Myelodysplastic Syndromes” – Various, 2009-To date
- “Campath in CLL” Various, 2009-2014
- “Elitek for tumor lysis prophylaxis” Various 2012
- “Colon Cancer” Brookwood Hospital, Birmingham, AL, September 29, 2010
- “Interpreting CBC”: Brookwood Hospital, Birmingham, AL, July 16, 2010
- “Ask an Oncologist” TV Interview, FOX 6 News, Birmingham, AL June 14, 2010
- “Cancer – diagnosis, screening, prevention and treatment options” – Brookdale Center, July 07, 2010
- “Myelodysplastic syndrome with emphasis on the prognostic relevance of karyotypic abnormalities” (Fellows talk), University of Alabama at Birmingham. October 23, 2009, Birmingham, AL
- “Myelodysplastic syndrome”. Dinner symposium for Hematologists-Oncologists, October 2, 2007. Dothan, AL
- “Myelodysplastic syndrome”. Dinner symposium for Hematologists-Oncologists, September 6, 2007. Birmingham, AL
- “Epigenetic therapy in Myelodysplastic syndrome”. Dinner symposium for Hematologists-Oncologists, August 30, 2007. Birmingham, AL
- “New treatment options in Myelodysplastic syndrome” Invited lectureship at University of Oklahoma, August 23, 2007, Oklahoma, OK
- “Expanding transplant eligibility to older adults – evolving role of non-myeloablative transplantation in older adults” – Leukemia Lymphoma Society/American Cancer Society meeting, August 11, 2007, Birmingham, AL
- “Role of imaging studies in Oncology with special emphasis on body CT scan and neuro imaging” Fellow teaching sessions. August 7, 2007, UAB, Birmingham, AL
- “Role of epigenetic modifications in Myelodysplastic syndrome” – Talk given to community Hematologists-Oncologists and support staff at Florence, AL – April 2007.
- “Role of epigenetic modifications in Myelodysplastic syndrome” – Talk given to community Hematologists-Oncologists and support staff at Florence, AL – April 2007.
- Invited Speaker and gave grand rounds on “Treatment strategies in Multiple Myeloma” at University of Calicut Medical College, Calicut, India – December 2006.
- Invited Speaker and gave grand rounds on “Myelodysplastic syndrome” at Carraway Methodist Medical Center, Birmingham, Alabama - November 2006.
- Invited Speaker and gave grand rounds on “Evolving Targeted Therapeutic Strategies in Malignant Tumors” at Medical College, Calicut, India – June 2003.

Khaleel K. Ashraf
MD, MBBS, DMRD, FACP

khaleelashraf@gmail.com kashraf@hoaallc.com [1-205-821-2467](tel:1-205-821-2467)

- Presented Hematology/Oncology Grand Rounds on “Indolent Lymphomas”: May 2005, University of Alabama at Birmingham.
- Review of Non Seminomatous Germ Cell Tumors, July 2004, UAB Comprehensive Cancer Center.
- Review on second line treatment for advanced non-small cell lung cancer; September 2004, UAB Comprehensive Cancer Center.
- Review of PET scan in diagnosis, staging and prognosis of malignant tumors: December 2004, UAB Comprehensive Cancer Center, Birmingham, AL
- Review of Iron overload states, November 2002, University of Tennessee Cancer Center, Memphis, TN
- Review of hyper coagulability, February 2003, University of Tennessee Cancer Center, Memphis, TN
- Review of oncologic emergencies, November 2012, University of Tennessee Cancer Center, Memphis, TN

CURRENT RESEARCH CERTIFICATIONS:

CITI Course Human Subject Research (Investigator Refresher Course)	1/16/2018-1/15/2021	ID 25813763
Investigator Site Personnel ICH GCP Training Version # 3	12/25/2017	
CITI Good Clinical Practice (ICH Focus) for Investigators	1/16/2018-1/15/2021	ID 25813765
CITI Health Information Privacy and Security Test (IPS for Investigators)	1/16/2018-1/15/2012	ID 25813764

SELECTED PRIOR RESEARCH ACTIVITIES:

1. **UAB 0624:** Standardization of CD3+ T-Cell Dose for Patients Receiving Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplants from Matched Related Donors (**Principal Investigator**)
2. **UAB 0655:** A Phase III, Randomized, Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-Vivo,Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Steroid Refractory Acute GvHD. (**Principal Investigator**)
3. **UAB 0741:** Comparison of in vitro cytotoxic effects, sensitivity and mechanism of action of T-araC (4' thio arabinofuranosylcytosine, SR9025) and Cytarabine on blasts from patients with newly diagnosed or relapsed acute leukemia. (**Principal Investigator**; IRB approval pending)
4. **BMT CTN 0102:** Phase 3 Trial of Tandem Autologous Stem Cell Transplant ± Post Second Autologous Transplant Maintenance Therapy vs. Single Autologous Stem Cell Transplant Followed by Matched Related Sibling Non-Myeloablative Allogeneic Stem Cell Transplants for Patients with Multiple Myeloma (Co Investigator)
5. **UAB 0462:** BMT CTN 0201 A Randomized Phase III Multi-Center Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors (Co Investigator)
6. **UAB 0354:** BMT CTN 0101 A Randomized, Double-Blind Trial of Fluconazole vs. Voriconazole for Prevention of Invasive Fungal Infections in Allogenic Blood and Bone Marrow Transplant Patients (Co Investigator)
7. **UAB 0654:** Amelioration of Oral Mucositis Pain by NASA Near Infra-Red-Light Emitting Diodes in Bone Marrow Transplant Patients (Co Investigator)
8. **UAB 0318:** A Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation Facilitated by The National Marrow Donor Program® (Co Investigator)
9. **UAB 0319:** A Research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries Facilitated by The National Marrow Donor Program® (Co Investigator)
10. **UAB 0663** – Open Label, One Arm Pilot Investigation of Lenalidomide Therapy for Patients with Relapsed and/or Refractory, Peripheral T-Cell Lymphomas.
11. **OGX-011-10** - Re treatment of Hormone Refractory **Prostate Cancer** patients who have had previous Taxotere with Taxotere and Prednisone versus Taxotere + Prednisone + custirsin, an antisense inhibitor of clusterin.
12. **MM-121-02-02-03** – Randomized trial of Exemestane versus exemestane+MM-121 in ER+/PR+/her2- post menopausal **breast cancer** patients with locally advanced or metastatic progression while on anti-estrogen treatment or progression during treatment within 6 months of discontinuing adjuvant Aromatase Inhibitors of Tamoxifen.
13. **CP14B012** - maintenance with Imetelstat+/-Avastin versus observation or Avastin alone in patients with stage IIIb/IV or recurrent locally advanced **lung cancer** who have completed 4-6 cycles of platinum doublet as 1st line chemo with no evidence of progression.

Khaleel K. Ashraf
MD, MBBS, DMRD, FACP

khaleelashraf@gmail.com kashraf@hoaallc.com [1-205-821-2467](tel:1-205-821-2467)

ACTIVITIES RELATED TO STEM CELL TRANSPLANTATION:

1. Developed the UAB standard operating procedure for non-myeloablative transplantation in low grade B cell malignancies including multiple myeloma - June 2007
2. FAHCT inspector training course, ASBMT Tandem Meeting, Feb. 6-13, 2007, Keystone, CO
3. ASBMT Tandem Meeting, Feb. 6-13, 2007, Keystone, CO, CIBMTR committee member.
4. Worked with Dr. Arabella Tilden, Ph.D., Director of Hematopoietic Stem Cell Collection and Processing Facility at University of Alabama at Birmingham and learned techniques regarding stem cell collection, various selection methods and purging and graft engineering - 2005
5. Worked with Dr. Larry Lamb, Ph.D., Co-Director of Hematopoietic Stem Cell Collection and Processing Facility at University of Alabama at Birmingham and learned techniques to use Clinemax flow cytometer to assess immune recovery and other engraftment kinetics - 2005
6. Worked with Dr. Andrew Lobashevsky, Co-Director of the HLA laboratory and familiar with HLA typing and its clinical applications in allogeneic stem cell transplantation
7. Did an extensive data analysis of the UAB BMT database to find the clinical relevance of T cell content of stem cell graft in allogeneic stem cell transplantation with regard to donor outcomes (GvHD, Relapse rate, immune reconstitution and overall survival). Based on the results, a clinical protocol was developed formulating an optimum T cell content for stem cell transplantation. (2004- 2006)
8. ASBMT Tandem Meeting, Feb. 9-15, 2005, Keystone, CO
9. Chronic Graft-versus-Host Disease—The Next Frontier in Transplantation Research, June 6, 2005, Bethesda, MD (Organized by NCI)

SELECTED POSTER/ABSTRACT PRESENTATIONS/MEETINGS:

1. Expert Panel on Cancer and Thrombosis, Philadelphia, PA 10/27/2018
2. Heron Advisory Board, Dallas, TX, 5/19/2018
3. CLL Advisory Board, Phoenix, AZ 3/10/2018
4. Ninlaro for Multiple Myeloma – Speaker Training, 3/18/2017 New York, NY
5. Multiple Myeloma Overview, February 18, 2017 Houston, TX
6. ASCO, Multiple Years
7. UAB Comprehensive Cancer Center retreat, October 29, 2007, Birmingham, AL
8. Oncology/Hematology conference of Alabama, September 8, 2007, Destin, AL
9. Updates on MDS, Multiple Myeloma July 19-20, 2007, Austin, TX
10. ASBMT, Feb 6-13, 2007 Key Stone, CO
11. ASCO June 2-6, 2006, Atlanta, GA
12. NOCR July 29-30, 2006, Chicago, IL
13. ASBMT Tandem Meeting, Feb. 9-15, 2005, Keystone, CO.
14. UAB Department of Medicine research Day 2004, Birmingham, AL.
15. American Society of Hematology Meeting, December 2004, San Diego, CA.
16. American Society of Clinical Oncology Meeting, June 2004, New Orleans, LA.
17. American Society of Hematology Meeting, December 2002, Philadelphia, PA
18. New York Chapter of the American College of Physicians - Downstate Associates Poster Competition, New York, NY 1999

COMMUNITY ACTIVITIES:

- Organized a bone marrow donor drive among South East Asians at the Hindu Temple and Cultural Center of Birmingham, coordinated with NMDP (National Marrow Donor Program) October 07, 2007.
- Secretary, AAPI (American Association of Physicians of Indian Origin), Birmingham and South West Alabama Chapter 2007-2010.
- President, AAPI (American Association of Physicians of Indian Origin), Birmingham and South West Alabama Chapter 2011-2013.

Khaleel K. Ashraf
MD, MBBS, DMRD, FACP

khaleelashraf@gmail.com kashraf@hoaallc.com [1-205-821-2467](tel:1-205-821-2467)

- Elected as Regional Director for AAPI (American Association of Physicians of Indian Origin), South East Central USA (AL, MS, TN and KY) for 2015-2017
- Member, UAB-COA Adolescent and Young Adult Oncology Program 2018-